WallStSmart

Becton Dickinson and Company (BDX)vsKestra Medical Technologies, Ltd. Common Stock (KMTS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Becton Dickinson and Company generates 26087% more annual revenue ($21.92B vs $83.72M). BDX leads profitability with a 8.0% profit margin vs -173.0%. BDX earns a higher WallStSmart Score of 61/100 (C+).

BDX

Buy

61

out of 100

Grade: C+

Growth: 5.3Profit: 5.5Value: 10.0Quality: 6.5
Piotroski: 6/9Altman Z: 1.49

KMTS

Avoid

31

out of 100

Grade: F

Growth: 6.3Profit: 2.0Value: 5.0Quality: 7.5
Piotroski: 6/9Altman Z: -1.20
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BDXUndervalued (+36.9%)

Margin of Safety

+36.9%

Fair Value

$286.42

Current Price

$158.27

$128.15 discount

UndervaluedFair: $286.42Overvalued

Intrinsic value data unavailable for KMTS.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BDX3 strengths · Avg: 8.3/10
Market CapQuality
$56.49B9/10

Large-cap with strong market position

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

EPS GrowthGrowth
28.6%8/10

Earnings expanding 28.6% YoY

KMTS2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
62.7%10/10

Revenue surging 62.7% year-over-year

Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

Areas to Watch

BDX4 concerns · Avg: 3.3/10
P/E RatioValuation
25.5x4/10

Moderate valuation

Revenue GrowthGrowth
1.6%4/10

1.6% revenue growth

Return on EquityProfitability
7.0%3/10

ROE of 7.0% — below average capital efficiency

Altman Z-ScoreHealth
1.492/10

Distress zone — elevated risk

KMTS4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.21B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-92.6%2/10

ROE of -92.6% — below average capital efficiency

Free Cash FlowQuality
$-28.16M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : BDX

The strongest argument for BDX centers on Market Cap, Price/Book, EPS Growth. PEG of 1.16 suggests the stock is reasonably priced for its growth.

Bull Case : KMTS

The strongest argument for KMTS centers on Revenue Growth, Debt/Equity. Revenue growth of 62.7% demonstrates continued momentum.

Bear Case : BDX

The primary concerns for BDX are P/E Ratio, Revenue Growth, Return on Equity.

Bear Case : KMTS

The primary concerns for KMTS are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

BDX profiles as a value stock while KMTS is a hypergrowth play — different risk/reward profiles.

KMTS is growing revenue faster at 62.7% — sustainability is the question.

BDX generates stronger free cash flow (549M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BDX scores higher overall (61/100 vs 31/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Becton Dickinson and Company

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.

Visit Website →

Kestra Medical Technologies, Ltd. Common Stock

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Kestra Medical Technologies, Ltd. is a wearable medical device and digital healthcare company. The company is headquartered in Kirkland, Washington.

Visit Website →

Want to dig deeper into these stocks?